Atacand candesartan cilexetilo 32mg - Popular in-network pharmacies near you

candesartan cilexetil, Atacand

Introduction Candesartan is an angiotensin II receptor blocker used widely in the therapy of hypertension and heart failure. Candesartan is associated with a low rate of transient serum aminotransferase elevations and has been linked to rare instances of acute liver injury.

Background Candesartan kan" de sar' tan is an angiotensin Candesartan receptor blocker ARB that is atacand used alone or in combination with other agents as therapy of hypertension and heart failure, atacand candesartan cilexetilo 32mg. Candesartan inhibits the renin-angiotensin system by blocking the angiotensin II type 1 receptor AT1 32mg, which prevents the vasoconstriction and volume expansion induced by circulating angiotensin II, accounting for its antihypertensive activity.

Candesartan was approved for 32mg in the United States atacand and is available in 4, 8, atacand candesartan cilexetilo 32mg, 16 and 32 mg tablets generically and under cilexetilo trade name Atacand. Current indications include treatment of hypertension usually in combination with other agents and to cilexetilo cardiovascular events and death in patients with chronic heart failure.

The typical dose of candesartan in adults is 16 to 32 mg once daily, and it is used candesartan term.

WARNING: FETAL TOXICITY

Candesartan is also available in fixed combinations with hydrochlorothiazide Atacand HCT and atacand. Side effects of candesartan are uncommon, but may include headache, dizziness, fatigue, cough, gastrointestinal upset and fetal toxicity.

Many ARBs, but not specifically candesartan, have been linked to cases of a candesartan sprue-like enteropathy that presents with severe diarrhea and weight loss and villous flattening and atrophy on intestinal biopsy arising after months or years of ARB use.

The enteropathy resembles celiac disease but does not repond to a gluten-free diet, but resolves promptly with 32mg the angiotensin receptor blocker.

These elevations were transient and rarely required dose cilexetilo. Rare instances of clinically apparent acute liver injury have been reported in association with candesartan therapy. The onset is usually within 1 to 8 weeks of starting therapy verapamil 200mg the serum enzyme pattern can be either hepatocellular or cholestatic with an acute hepatitis- or cholestatic hepatitis-like clinical syndrome.

In some instances, cholestasis can be prolonged and relapsing, but candesartan therapy has not been associated with vanishing bile duct syndrome or chronic liver injury. Immunoallergic manifestations rash, fever, eosinophilia are not common, atacand candesartan cilexetilo 32mg, nor is autoantibody formation.

C Probable cause of rare instances of clinically apparent liver injury.

Candesartan CILEXETIL

Mechanism of Injury The cause of the minor serum aminotransferase elevations and the acute liver injury associated with candesartan is not known, but resembles idiosyncratic liver injury due to a hypersensitivity reaction. Candesartan has minor liver metabolism through the cytochrome P system CYP 2C9 and has minimal drug-drug interactions.

Outcome and Management The instances of acute liver injury reported with candesartan use have been self limited and have not resulted in acute liver failure or chronic liver injury. While corticosteroids have been used in cases of severe cholestasis due to ARBs, their efficacy has not been shown and their use is best avoided.

Patients with candesartan induced acute liver injury should probably avoid use of other ARBs, although cross sensitivity to liver injury among the members of this class of agents has not been shown.

References on the safety and potential hepatotoxicity of candesartan are given in the Overview section on the angiotensin II receptor antagonists, atacand candesartan cilexetilo 32mg.